Mobile website
Archive > Volume 32 Issue 4 > 2025,32(4):413-417. DOI:10.3872/j.issn.1007-385X.2025.04.010 Prev Next
Clinical Research
DC-CIK cell as an adjuvant to cetuximab combined with CAPEOX chemotherapy regimen for the treatment of 52 cases of advanced colorectal cancer
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
[Abstract] Objective: To evaluate the clinical efficacy and safety of DC-CIK cell immunotherapy as an adjuvant to cetuximab combined with CAPEOX (oxaliplatin + capecitabine) chemotherapy regimen in the treatment of advanced colorectal cancer (CRC) with all RAS gene wild-type and BRAF gene wild-type. Methods: A retrospective analysis was conducted on the clinical data of 52 cases of advanced CRC treated in the Oncology Department of in the General Hospital of the Eastern Theatre Command between December 2020 and October 2023, with 26 cases in the control group and the observation group respectively. The observation group received DC-CIK cell therapy in addition to chemotherapy given to the control group. The clinical efficacy and adverse reactions of patients were recorded, and the recent efficacy, quality of life score, incidence of chemotherapy adverse reactions, the changes in tumour markers, and immune indicators before and after treatment were analysed. Results: Compared with those in the control group, the disease control rate (DCR) and quality of life of advanced CRC patients in the observation group were significantly improved (both P < 0.05). The incidence of diarrheal/constipation and tumour marker CA72-4 were significantly reduced (all P < 0.05), and the NK cell count increased significantly (P < 0.05). Conclusion: DC-CIK cell immunotherapy, when used as an adjuvant to cetuximab in combination with the CAPEOX chemotherapy regimen in patients with advanced CRC, is safe and feasible. It can significantly improve the DCR and bring significant clinical benefits to patients.
Keywords:
Project Supported:
Clc Number:
